– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab vedotin plus pembrolizumab improved median overall survival by more than 15 months vs. chemotherapy – – Results will form the basis of global…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.